Literature DB >> 1616637

Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. The Italian Seroconversion Study.

.   

Abstract

OBJECTIVE: To evaluate the risk of developing AIDS and to identify early markers of disease progression in injecting drug users (IDU).
DESIGN: Prospective study.
SETTING: Sixteen centres throughout Italy. PATIENTS, PARTICIPANTS: Four hundred and sixty-eight IDU for whom it was possible to estimate the date of HIV seroconversion. MAIN OUTCOME MEASURES: Progression to AIDS.
RESULTS: Twenty-six subjects developed AIDS during a median follow-up period of 42 months. The risk of developing AIDS was 21% within 7 years following seroconversion. Age greater than 25 years at seroconversion was associated with more rapid disease progression. Progression was similar for men and women. Continued drug injection did not accelerate progression to AIDS. Among the laboratory markers studied, CD4+ cell count at the first HIV-positive test was the best predictor of disease progression. Results were confirmed using multivariate analysis.
CONCLUSIONS: Our findings indicate the importance of the role played by age in accelerated disease progression, which may be determined by a more rapid decline in CD4+ cell number in older HIV-infected IDU.

Entities:  

Mesh:

Year:  1992        PMID: 1616637

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

1.  Estimating the size of the HIV epidemic among injecting drug users in Amsterdam.

Authors:  H J van Haastrecht; P J Bindels; A A van den Hoek; R A Coutinho
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

2.  Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users.

Authors:  F Montella; P Pezzotti; F Di Sora; O Recchia; F Lauria; G Rezza
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

3.  The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use.

Authors:  Farzana Kapadia; Judith A Cook; Marge H Cohen; Nancy Sohler; Andrea Kovacs; Ruth M Greenblatt; Imtiaz Choudhary; David Vlahov
Journal:  Addiction       Date:  2005-07       Impact factor: 6.526

4.  Accounting for dropout reason in longitudinal studies with nonignorable dropout.

Authors:  Camille M Moore; Samantha MaWhinney; Jeri E Forster; Nichole E Carlson; Amanda Allshouse; Xinshuo Wang; Jean-Pierre Routy; Brian Conway; Elizabeth Connick
Journal:  Stat Methods Med Res       Date:  2015-06-15       Impact factor: 3.021

5.  Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group.

Authors:  M Dorrucci; G Rezza; M Andreoni; P Pezzotti; E Nicastri; L Ventura; M Zignani; M B Alliegro; G Tarantini; B Salassa; V Colangeli; G Mazzarello; M A Ursitti; M Barbanera; R Pristerà; F Castelli; L Ortona
Journal:  Eur J Epidemiol       Date:  1999-04       Impact factor: 8.082

6.  Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults. Aquitaine cohort, France, 1985-1997.

Authors:  E Malvy; R Thiébaut; C Marimoutou; F Dabis
Journal:  J Am Coll Nutr       Date:  2001-12       Impact factor: 3.169

7.  Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?

Authors:  S Lindbäck; C Broström; A Karlsson; H Gaines
Journal:  BMJ       Date:  1994-12-10

8.  MODELING LEFT-TRUNCATED AND RIGHT-CENSORED SURVIVAL DATA WITH LONGITUDINAL COVARIATES.

Authors:  Yu-Ru Su; Jane-Ling Wang
Journal:  Ann Stat       Date:  2012-09-05       Impact factor: 4.028

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.